McClellan said the company implemented most corrective actions by the end of 2025 and is now focused on demonstrating that improvements are “effective and sustainable over time” before resubmission. Based on current progress, he said the company remains on track to resubmit in the second quarter of 2026, which “would position us for FDA decisions before the end of the year.” In the Q&A, he added the company is working to submit by the end of the first quarter but is prepared that it could slip into the seco ...

Alvotech (NasdaqGM:ALVO) Q4 2025 Earnings call March 19, 2026 08:00 AM ET Company ParticipantsBenedikt Stefansson - Senior Director of Investor Relations & Global CommunicationsGlen Santangelo - Managing DirectorJoseph E. McClellan - COOLinda Jónsdóttir - CFOLisa Graver - Chief Executive Officer DesignateRóbert Wessman - Founder and Executive ChairmanConference Call ParticipantsArvid Näsander - Equity Research AnalystAshwani Verma - Equity AnalystChristopher Uhde - Senior Pharma and Biotech Equity AnalystOp ...

Alvotech (NasdaqGM:ALVO) Q4 2025 Earnings call March 19, 2026 08:00 AM ET Company ParticipantsBenedikt Stefansson - Senior Director of Investor RelationsGlen Santangelo - Managing DirectorJoseph E. McClellan - COOLinda Jónsdóttir - CFOLisa Graver - Chief Executive Officer DesignateRóbert Wessman - Founder and Executive ChairmanConference Call ParticipantsArvid Näsander - Equity Research AnalystAshwani Verma - Equity AnalystChristopher Uhde - Senior Pharma and Biotech Equity AnalystOperatorGood day, and than ...